BioSpace News Archive

ReWalk Robotics Ltd., a leading manufacturer of robotic medical technology for people with lower extremity disabilities, announced the appointment of Michael Lawless, CPA, as Chief Financial Officer, effective September 19, 2022.

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase) today announced that Milton Werner, Ph.D., President and Chief Executive Officer of Inhibikase, will present at the International Congress of Parkinson’s Disease and Movement Disorders.

PolarityTE, Inc. announced that Jeff Dyer, PhD, has decided to resign from its Board of Directors, effective immediately.

Cryoport, Inc. (Nasdaq: CYRX) (“Cryoport” or the “Company”), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced it has entered into a strategic relationship with BioLife Plasma Services, part of the global biopharmaceutical company Takeda.

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), today announced that final data from its phase II study of paxalisib in patients with newly diagnosed glioblastoma will be the subject of an oral presentation at the upcoming annual congress of the European Society for Medical Oncology (ESMO), which will be held in person from 9-13 September 2022 in Paris, France.

QT Imaging, Inc., a medical device company focused on the development and clinical adoption of novel products for body imaging, announced findings of a study analyzing changes in breast glandular and ductal volume during the menstrual cycle for pre-menopausal, peri-menopausal and post-menopausal women.

ValGenesis Inc. announces the final speaker lineup of ValConnect 2022, its annual user conference that runs from Monday, September 26th through Wednesday September 28th.

EXUMA Biotech, Corp. announced that its Chief Business Officer and Head of Finance, Dr. Gregory Wade, will provide a corporate presentation at 11:25 AM ET on Wednesday, September 14, 2022, as part of the annual Baird Global Healthcare Conference in New York.

Autobahn Therapeutics, a biotechnology company focused on restoring hope for people affected by CNS disorders, today announced the closing of a $32.7 million financing to support the company’s continued commitment to transforming the treatment of CNS disorders, led by a strategic prioritization on addressing treatment-resistant depression (TRD).

Alumis Inc., a precision immunology company that is reimagining the discovery, development and treatment of autoimmune disorders, announced that Jörn Drappa, M.D., Ph.D., has been appointed as chief medical officer.